FMP

FMP

Enter

ETON - Eton Pharmaceut...

photo-url-https://images.financialmodelingprep.com/symbol/ETON.png

Eton Pharmaceuticals, Inc.

ETON

NASDAQ

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

11.83 USD

-0.67 (-5.66%)

Historical Prices

From:

To:

11.2811.411.611.81212.212.2309:30 AM09:49 AM10:08 AM10:31 AM10:50 AM11:09 AM11:27 AM11:47 AM12:08 PM12:28 PM12:46 PM01:04 PM01:23 PM01:42 PM02:00 PM02:18 PM02:37 PM02:57 PM03:15 PM03:35 PM03:53 PM

About

ceo

Mr. Sean E. Brynjelsen

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in c...

CIK

0001710340

ISIN

US29772L1089

CUSIP

29772L108

Address

21925 West Field Parkway

Phone

847 787 7361

Country

US

Employee

31

IPO Date

Nov 13, 2018

Financial Statement

-6M-3M03M6M9M12M2023 Q42024 Q12024 Q22024 Q32024 Q4RevenueNet Income

Earnings

-0.15-0.1-0.0500.050.10.152023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q42025 Q1EPS Consensus

ETON Financial Summary

CIK

0001710340

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

29772L108

ISIN

US29772L1089

Country

US

Price

11.83

Beta

1.34

Volume Avg.

284.09k

Market Cap

317.25M

Shares

-

52-Week

3.03-18.41

DCF

-15.06

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-78.87

P/B

-

Website

https://www.etonpharma.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest ETON News

GlobeNewsWire

Aug 22, 2024

Eton Pharmaceuticals to Participate at the H.C. Wainwright 2...

DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the Company will participate at the H.C. Wainwright 26th Annual Global Investment Conference in New York City.

Seeking Alpha

Aug 11, 2024

Eton Pharmaceuticals, Inc. (ETON) Q2 2024 Earnings Call Tran...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to the Eaton Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please be advised, this call is being recorded at ...

GlobeNewsWire

Jul 30, 2024

Eton Pharmaceuticals to Report Second Quarter 2024 Financial...

DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

Seeking Alpha

May 11, 2024

Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript

Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript May 9, 2024 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to the Eton Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time all participants are in listen-only mode.

GlobeNewsWire

May 1, 2024

Eton Pharmaceuticals to Present at the Citizens JMP Life Sci...

DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows:

GlobeNewsWire

Apr 29, 2024

Eton Pharmaceuticals to Report First Quarter 2024 Financial ...

DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

Seeking Alpha

Mar 14, 2024

Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Tran...

Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript

Zacks Investment Research

Mar 14, 2024

Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Reve...

Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.04 per share a year ago.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep